Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048382 | 1.00 | USP2 (0.34) | USP2ARLMNAALDH1A1CYP1A2 | |
| SCHEMBL17048264 | 1.00 | USP2 (0.34) | USP2ARLMNAALDH1A1CYP1A2 | |
| SCHEMBL4420207 | 0.89 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL10447623 | 0.83 | THRB (0.36) | — | |
| SCHEMBL3608074 | 0.83 | TSHR (0.32) | TSHR | |
| SCHEMBL5241702 | 0.83 | KDM4E (0.34) | KDM4E | |
| SCHEMBL1628831 | 0.83 | TSHR (0.32) | TSHR | |
| SCHEMBL2962445 | 0.83 | TSHR (0.32) | TSHR | |
| SCHEMBL59285 | 0.81 | AR (0.36) | AR | |
| SCHEMBL59286 | 0.81 | AR (0.36) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117736236-A | Preparation method of hydroxyl-protected intermediate, phosphatidylethanolamine compound and preparation method thereof | 凯莱英生命科学技术(天津)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-3394080-B1 | LIPID-LINKED PRODRUGS | UNIV BRITISH COLUMBIA (CA) | 2023-06-07 | — | — | EP | disclosed |
| CN-111712240-A | Fatty acid derivatives for the treatment of non-alcoholic steatohepatitis | 巴斯夫股份公司 | 2020-09-25 | — | — | CN | disclosed |
| US-10780174-B2 | Lipid-linked prodrugs | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-09-22 | — | — | US | disclosed |
| US-20190151458-A1 | Lipid-Linked Prodrugs | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-05-23 | — | — | US | disclosed |
| EP-3110789-B1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-20180110747-A1 | USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3 | BASF AS (NO) | 2018-04-26 | — | — | US | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-9796659-B2 | Derivatives of polyhydroxy compounds | RATIOPHARM GMBH (DE) | 2017-10-24 | — | — | US | disclosed |
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2017-01-05 | — | — | US | disclosed |
| EP-3110789-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | ratiopharm GmbH (DE) | 2017-01-04 | — | — | EP | disclosed |
| WO-2016050210-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050209-A1 | HETEROFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE, PREPARATION METHOD, AND BIO-RELATED SUBSTANCE | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
| WO-2015128488-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | RATIOPHARM GMBH (DE) | 2015-09-03 | — | — | WO | disclosed |
| US-5321143-A | Reacting tartaric acid, ester or amide with thionyl chloride; cyclization, in situ oxidation | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1994-06-14 | — | — | US | disclosed |
| US-5112990-A | Oxidation of cyclic sulfites produced from dihydroxy compounds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0417187-A1 | RUTHENIUM-CATALYZED PRODUCTION OF CYCLIC SULFATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1991-03-20 | — | — | EP | disclosed |
| WO-1989011478-A1 | RUTHENIUM-CATALYZED PRODUCTION OF CYCLIC SULFATES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001945-A1 | DERIVATIVES OF POLYHYDROXY COMPOUNDS | TPMT, FH, FAH | USP2 1561/4885AR 3999/4885LMNA 4394/4885 |
| US-10780174-B2 | Lipid-linked prodrugs | SGMS2, SGMS1, LIPA | USP2 1458/4885AR 2161/4885LMNA 2162/4885 |
| US-20190151458-A1 | Lipid-Linked Prodrugs | SGMS2, SGMS1, LIPA | USP2 1458/4885AR 2161/4885LMNA 2162/4885 |
| US-20180110747-A1 | USE OF THIA OXO COMPOUNDS FOR LOWERING APO C3 | APOB, TTPA, APOL1 | USP2 4360/4885AR 3236/4885LMNA 903/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | USP2 1433/4885AR 4594/4885LMNA 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.